Second, the sample size of the validation cohort was small and only melanoma and NSCLC were included, and so, the association between PRKDC mutation‐induced changes in the immune microenvironment and improvements of ICI treatment efficacy needs to be confirmed and verified in a larger population with multiple cancer types, such as MSS colorectal cancer and pancreatic cancer. This evidence concerns the gene PRKDC and familial pancreatic carcinoma.